| Document |
Document Title |
|
WO/2019/093623A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting diode using the same.
|
|
WO/2019/085758A1 |
Disclosed in the present invention are a ketone-containing compound and applications thereof in organic electroluminescent devices. The compound consists of ketone and spiroanthracenefluorene groups, has a very deep HOMO energy level and...
|
|
WO/2019/090088A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/081299A1 |
The present invention relates to novel amine substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compos...
|
|
WO/2019/082717A1 |
The purpose of the present invention is to provide: a novel curable compound which can be expected to be used as a raw material for photocurable resins and thermosetting resins; a method for synthesizing said compound; a resin compositio...
|
|
WO/2019/081477A1 |
The invention relates to substituted pyrazoles of general formula (I) or salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the use thereof as herbicides, in particular for controllin...
|
|
WO/2019/076316A1 |
Provided is a preparation method for a tyrosine kinase inhibitor and an intermediate thereof. Specifically, a preparation method for a cyanoquinoline compound is provided. The method has a high yield, good product purity, and mild reacti...
|
|
WO/2019/073325A1 |
The present invention relates to a novel process for the preparation of lifitegrast of Formula (I). The present invention further provides a novel process for the purification of lifitegrast of Formula (I).
|
|
WO/2019/074870A1 |
The present disclosure relates compositions and methods for combinatorial drug discovery in nanoliter droplets. More particularly, the disclosure relates to novel synergistic agents that increase efficacy of antibiotic agents to treat ba...
|
|
WO/2019/068783A1 |
The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
|
|
WO/2019/068782A1 |
The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
|
|
WO/2019/070044A1 |
A purpose of the present invention is to provide a heterocyclic compound that has an AMPA receptor function enhancing action, and can be expected to be useful as a prevention or treatment for depression, Alzheimer's disease, schizophreni...
|
|
WO/2019/065928A1 |
The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of inflammatory diseases of the central nervous system, or a pharmacologically acceptable salt thereof. Provided is a compound represent...
|
|
WO/2019/054386A1 |
Provided is a heterocyclic compound represented by general formula (I), or a pharmacologically acceptable salt of the heterocyclic compound. In general formula (I): X represents O or NH; R1 represents a substituted or unsubstituted aryl ...
|
|
WO/2018/139767A9 |
The present invention provides a novel amine-based compound and an organic light emitting device using the same.
|
|
WO/2019/046316A1 |
The present invention relates to compounds of formula (I) (shown below) useful as inhibitors of phosphatidylinositol- 3 -phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.
|
|
WO/2019/045581A1 |
New 5-aminotetrazole derivatives with antimicrobial and antifungal activity are disclosed.
|
|
WO/2019/037860A1 |
Compounds of formula (I) wherein A, R, W, Q, L, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
|
|
WO/2019/038717A1 |
The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1,R2, Rx, XI, n, nl, and q are as defined herein, methods of making ...
|
|
WO/2019/040389A1 |
The present invention relates novel furan based amine cross-linkers with improved thermomechanical and water barrier properties. The novelty of this invention is the use of aromatic, and hydrophobic aliphatic aldehydes to bridge two furf...
|
|
WO/2019/040104A2 |
The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.
|
|
WO/2019/035408A1 |
The present invention provides a method for producing a compound (i) having a group represented by a partial structure (A), a partial structure (AI), a partial structure (D), or a partial structure (DI), and a group represented by a part...
|
|
WO/2019/034686A1 |
The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; ...
|
|
WO/2019/036534A1 |
Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising t...
|
|
WO/2019/031880A1 |
The present invention relates to kidamycin derivative L1-95-1, and a composition for preventing or treating cancer, containing the same as an active ingredient. L1-95-1 has inhibited cell proliferation and EGF-induced malignization of JB...
|
|
WO/2019/030604A1 |
Provided is a novel compound. Also provided is a light-emitting element having excellent light-emitting efficiency and element service life. The compound is an organic compound represented by the general formula (G0) and having a dibenzo...
|
|
WO/2019/027040A1 |
A compound represented by formula (1) (in the formula, R1-R8, R11-R18, R21-R28, R31-R38, X, Y, L1, L2, L3, and Ar are as defined in the specification) provides an organic electroluminescent element having a low drive voltage and exceptio...
|
|
WO/2019/023450A1 |
Described herein are compounds of the formulae (l)-(lII) and (la)-(llla) and pharmaceutically acceptable salts, isomers, mixture of isomers, crystalline forms, non-crystalline forms, hydrates, or solvates thereof, as well as methods usin...
|
|
WO/2019/016269A1 |
The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.
|
|
WO/2019/011200A1 |
The invention relates to a preparation method of a pyridinecarboxamide derivative and an intermediate thereof wherein the reaction step is shortened, the reaction yield is improved, the method is simple and easy to control, and is advant...
|
|
WO/2019/002183A1 |
The invention relates to a method for producing substituted nitrogen-containing heterocycles which can be used, in particular, in electronic devices.
|
|
WO/2019/002571A1 |
This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prev...
|
|
WO/2019/003237A1 |
The present invention discloses novel indolylkojyl compounds of formula 1 The invention also provides a one pot, green chemistry method for preparation of indolylkojyl compounds. The compounds of the present invention are selectively tox...
|
|
WO/2018/232805A1 |
Provided are a puerarin derivative represented by formula (I) or formula (II) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a use thereof for the prevention and treatment of cardiovascular and cerebrov...
|
|
WO/2018/234343A1 |
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
|
|
WO/2018/234284A1 |
The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2018/229193A1 |
The present invention relatesto a pharmaceutical composition comprising acompound of the formula Ias described belowor a tautomeror a pharmaceutically acceptable salt thereof; to the compound of the formula Ias described below or a tauto...
|
|
WO/2018/231618A1 |
The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kap...
|
|
WO/2018/229237A1 |
The present invention relates to the production of tri-functional aromatic molecules from diformylfuran, in particular to the production of tri-methyl benzene derivatives such as for example trimellitic acid or 1,2,4-tri(aminomethyl)benz...
|
|
WO/2018/220634A1 |
The invention generally provides a method for the synthesis of a π-conjugated system from oligofurans, under conditions involving cycloaddition.
|
|
WO/2018/216013A1 |
The present invention provides turn-ON dioxetane-based chemiluminescence probes based on the Schapp's adamantylidene-dioxetane probe, which emit light in the near-infrared (NIR) region and are therefore useful for in vivo imaging, as wel...
|
|
WO/2018/215798A1 |
The present invention relates to compounds of formula I that function as inhibitors of BCL6(B- cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates ...
|
|
WO/2018/210297A1 |
Disclosed are an intermediate of Eribulin and a preparation method therefor. In particular, disclosed are compounds as represented by formula II, formula III and formula V and a preparation method therefor. Ar is C1-10 alkyl substituted,...
|
|
WO/2018/200471A1 |
The present invention is directed to reactor systems and processes for producing organic acids through thermolysis of polylactones. In preferred embodiments, the reactor systems and processes are capable of introducing at least one epoxi...
|
|
WO/2018/192083A1 |
Methods and compounds for preventing and /or treating Zika virus(ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.
|
|
WO/2018/195155A1 |
The present embodiments related to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-m...
|
|
WO/2018/188643A1 |
Relating to an opioid receptor agonist (1S,4S)-4-ethoxy-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]d
eca-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine fumarate salt, a fumarate salt I crystal form thereof, and a preparation method and ...
|
|
WO/2018/188795A1 |
The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXRß) and act preferably as inverse agonists of LXR.
|
|
WO/2018/179998A1 |
The purpose of the present invention is to provide: a novel procyanidin having an excellent polysaccharide digestion inhibition effect; and a method for producing the same. Provided is a procyanidin characterized by having a basic skelet...
|
|
WO/2018/169055A1 |
It is known that foods containing a carbohydrate, e.g., starch, in a large amount generate acrylamide upon heating at high temperatures. Some documents state that acrylamide is formed by the Maillard reaction of an amino acid, e.g., aspa...
|
